NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled
NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT01975831 2022-10-12A Phase 1 Study to Evaluate MEDI4736 in Combination With TremelimumabLudwig Institute for Cancer ResearchPhase 1 Completed104 enrolled 23 charts
NCT02669914 2018-11-06MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsWashington University School of MedicinePhase 2 Terminated4 enrolled 12 charts